SCHEMBL26607239

SCHEMBL26607239

Cc1cc(C(C)(C)C)ccc1-c1cc(=O)c2nc(OCCN(C)C)ccc2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.50
▸ KIT P10721 1/20 0.37
▸ HTR7 P34969 2/20 0.35
▸ PIM1 P11309 2/20 0.35
▸ PIM3 Q86V86 2/20 0.35
▸ HRH4 Q9H3N8 1/20 0.35
▸ NR1I2 O75469 1/20 0.34
▸ ESR1 P03372 2/20 0.34
▸ TLR7 Q9NYK1 1/20 0.33
▸ CYP26A1 O43174 1/20 0.33
▸ CYP26B1 Q9NR63 1/20 0.33
▸ NUAK1 O60285 1/20 0.33
▸ HTR1D P28221 1/20 0.33
▸ TNKS O95271 1/20 0.32
▸ PSEN1 P49768 1/20 0.32
▸ PSEN2 P49810 1/20 0.32
▸ APH1B Q8WW43 1/20 0.32
▸ NCSTN Q92542 1/20 0.32
▸ APH1A Q96BI3 1/20 0.32
▸ PSENEN Q9NZ42 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26724153 0.83 CYP26A1 (0.38) KDM4ECYP26A1CYP26B1
SCHEMBL26607054 0.80 KDR (0.36) KDM4ECYP26A1CYP26B1KDR
SCHEMBL26607006 0.79 KDM4E (0.46) KDM4EKITHRH4NUAK1TNKS
SCHEMBL26724147 0.75 CYP26A1 (0.39) CYP26A1CYP26B1
SCHEMBL26725495 0.73 ADORA2A (0.34) KDM4E
SCHEMBL26607383 0.70 ADORA2A (0.36) KDM4ECYP26A1CYP26B1
SCHEMBL24123876 0.69 KDM4E (1.00) KDM4EHTR7NR1I2ESR1
SCHEMBL26606931 0.67 HPGD (0.54) KDM4ECYP26A1CYP26B1CLK4
SCHEMBL26724787 0.67 HPGD (0.59) KDM4E
SCHEMBL26607318 0.67 CYP26A1 (0.41) KDM4ECYP26A1CYP26B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4511114-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 — — EP disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
WO-2023205778-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed
WO-2023205778-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN TRPV1, SCN3A, KCNN3 KDM4E 4346/4885KIT 3965/4885HTR7 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback